Single CRISPR Injection Cuts Hereditary Angioedema Attacks by 87% in Phase 3 Trial
Intellia's one-time in vivo CRISPR therapy achieved an 87% attack reduction in Phase 3, marking genetic medicine's biggest clinical milestone yet.
Summary
Intellia Therapeutics has reported the world's first positive Phase 3 result for an in vivo CRISPR gene editing therapy. Their treatment, lonvo-z, targets hereditary angioedema — a rare condition causing life-threatening swelling attacks — with a single infusion. In the HAELO trial, patients saw an 87% reduction in monthly attacks versus placebo, and 62% remained completely attack-free over six months compared to just 11% on placebo. Quality-of-life scores improved by over 17 points, far exceeding the 6-point threshold considered clinically meaningful. The therapy works by permanently reducing production of kallikrein, the protein that triggers attacks, rather than requiring ongoing medication. Safety data were encouraging, with only mild-to-moderate side effects reported. Results were published in the New England Journal of Medicine.
Detailed Summary
For decades, gene editing has been a scientific promise struggling to become clinical reality. That changed with Intellia Therapeutics announcing Phase 3 results for lonvoguran ziclumeran, a one-time CRISPR-based therapy for hereditary angioedema, a rare inherited disease causing sudden, potentially fatal swelling episodes. Published in the New England Journal of Medicine and presented at the EAACI Congress 2026, this marks the world's first positive pivotal Phase 3 trial for an in vivo CRISPR therapy — one that edits genes directly inside the living patient rather than in a laboratory dish.
The numbers from the HAELO trial are striking. Patients receiving a single infusion of lonvo-z experienced an 87% reduction in average monthly attack rates versus placebo. Sixty-two percent of treated patients remained entirely attack-free over the six-month evaluation period, compared to just 11% in the placebo arm. Moderate-to-severe attacks dropped by 91%, and attacks requiring emergency on-demand treatment fell by 89%.
Beyond attack frequency, quality-of-life scores improved by more than 17 points on average — nearly three times the 6-point threshold researchers define as clinically meaningful. For HAE patients, who often live in constant fear of unpredictable, life-threatening episodes, this represents a profound functional improvement.
The mechanism is durable by design. Lonvo-z uses CRISPR to permanently reduce kallikrein production — the key protein driver of HAE attacks. Kallikrein levels stabilized by week five and held steady through the latest data cutoff, suggesting lasting effect from a single treatment. Safety signals were reassuring: side effects were mild to moderate, and no serious adverse events occurred in the treatment group.
While HAE is rare, the broader implications matter enormously for longevity medicine. This trial validates that in vivo CRISPR platforms can deliver safe, durable, large-scale clinical results — opening the door to future gene editing interventions targeting aging-related diseases, cardiovascular risk, and genetic contributors to chronic illness.
Key Findings
- A single infusion of lonvo-z reduced monthly HAE attacks by 87% versus placebo over six months.
- 62% of treated patients were completely attack-free, compared to only 11% in the placebo group.
- Quality-of-life scores improved by 17+ points, nearly 3x the 6-point clinically meaningful threshold.
- Kallikrein levels stabilized by week five and remained steady, suggesting durable one-time efficacy.
- No serious adverse events were observed in the treatment arm during the primary observation period.
Methodology
This is a news report summarizing Phase 3 clinical trial results published in the New England Journal of Medicine, a top-tier peer-reviewed journal. The source, Longevity.Technology, is a credible longevity-focused outlet. Evidence is based on randomized controlled trial data presented at EAACI 2026 and simultaneously published, lending strong scientific credibility.
Study Limitations
The article is a news summary and does not provide full trial data, statistical methodologies, or long-term follow-up beyond six months. HAE is a rare condition, so generalizability to common diseases requires further research. Independent replication and regulatory review are still needed before broader clinical adoption.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.